These results are very reassuring. 8% ahead of half year guidance, net profit in second half, $12m reduction in debt and more promised as restructuring costs subside.
Just as important, revenues have stabilised, and they talk of moving from back to basics to growth in 2017.
Great recovery play, trading 12% below NAV.
Target price 40c.